Cited by 81Congenital Heart Disease StudiesCardiovascular Conditions and TreatmentsHemodynamic Monitoring and Therapy

Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease

Open access
Burkhardt, Barbara EU, Rücker, Gerta, Stiller, Brigitte·2015·Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Children with congenital heart disease often undergo heart surgery at a young age. They are at risk for postoperative low cardiac output syndrome (LCOS) or death. Milrinone may be used to provide inotropic and vasodilatory support during the immediate postoperative period. OBJECTIVES: This review examines the effectiveness of prophylactic postoperative use of milrinone to prevent LCOS or death in children having undergone surgery for congenital heart disease. SEARCH METHODS: Electronic and manual literature searches were performed to identify randomised controlled trials. We searched CENTRAL, MEDLINE, EMBASE and Web of Science in February 2014 and conducted a top-up search in September 2014 as well as clinical trial registries and reference lists of published studies. We did not apply any language restrictions. SELECTION CRITERIA: Only randomised controlled trials were selected for analysis. We considered studies with newborn infants, infants, toddlers, and children up to 12 years of age. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data according to a pre-defined protocol. We obtained additional information from all study authors. MAIN RESULTS: Three of the five included studies compared milrinone versus levosimendan, one study compared milrinone with placebo, and one compared milrinone verus dobutamine, with 101, 242, and 50 participants, respectively. Three trials were at low risk of bias while two were at higher risk of bias. The number and definitions of outcomes were non-uniform as well. In one study comparing two doses of milrinone and placebo, there was some evidence in an overall comparison of milrinone versus placebo that milrinone lowered risk for LCOS (risk ratio (RR) 0.52, 95% confidence interval (CI) 0.28 to 0.96; 227 participants). The results from two small studies do not provide enough information to determine whether milrinone increases the risk of LCOS when compared to levosimendan (RR 1.22, 95% CI 0.32 to 4.65; 59 participants). Mortality rates in the studies were low, and there was insufficient evidence to draw conclusions on the effect of milrinone compared to placebo or levosimendan or dobutamine regarding mortality, the duration of intensive care stay, hospital stay, mechanical ventilation, or maximum inotrope score (where available). Numbers of patients requiring mechanical cardiac support were also low and did not allow a comparison between studies, and none of the participants of any study received a heart transplantation up to the end of the respective follow-up period. Time to death within three months was not reported in any of the included studies. A number of adverse events was examined, but differences between the treatment groups could not be proven for hypotension, intraventricular haemorrhage, hypokalaemia, bronchospasm, elevated serum levels of liver enzymes, or a reduced left ventricular ejection fraction < 50% or reduced left ventricular fraction of shortening < 28%. Our analysis did not prove an increased risk of arrhythmias in patients treated prophylactically with milrinone compared with placebo (RR 3.59, 95% CI 0.83 to 15.42; 238 participants), a decreased risk of pleural effusions (RR 1.78, 95% CI 0.92 to 3.42; 231 participants), or a difference in risk of thrombocytopenia on milrinone compared with placebo (RR 0.86, 95% CI 0.39 to 1.88; 238 participants). Comparisons of milrinone with levosimendan or with dobutamine, respectively, did not clarify the risk of arrhythmia and were not possible for pleural effusions or thrombocytopenia. AUTHORS' CONCLUSIONS: There is insufficient evidence of the effectiveness of prophylactic milrinone in preventing death or low cardiac output syndrome in children undergoing surgery for congenital heart disease, compared to placebo. So far, no differences have been shown between milrinone and other inodilators, such as levosimendan or dobutamine, in the immediate postoperative period, in reducing the risk of LCOS or death. The existing data on the prophylactic use of milrinone has to be viewed cautiously due to the small number of small trials and their risk of bias.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd009515.pub2

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 69 references couldn’t be matched to a known paper.

Research works printed but not linked: 9

  1. Cavigelli‐Brunner A, Hug MI, Dave H, Cannizzaro V, Baenziger O, Buerki C, et al. Therapy of low cardiac output syndrome after cardiac surgery in infants and children: a double blind randomized study comparing dobutamine and milrinone. Cardiology in the Young. May 2013; Vol. 23, Supplement S1:S34; O11‐3.
  2. Hoffman TM, Wernovsky G, Atz AM, Bailey JM, Akbary A, Kocsis JF, et al. Prophylactic intravenous use of milrinone after cardiac operation in pediatrics (PRIMACORP) study. American Heart Journal 2002;143(1):15‐21. [DOI] [PubMed] [Google Scholar]
  3. Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003;107(7):996‐1002. [DOI] [PubMed] [Google Scholar]
  4. Hoffman TM, Wernovsky G, Atz AM, Bailey JM, Akbary A, Kocsis JF, et al. Prophylactic intravenous use of milrinone after cardiac operation in pediatrics (PRIMACORP) study.. American Heart Journal 2002;143(1):15‐21. [DOI] [PubMed] [Google Scholar]
  5. Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003;107(7):996‐1002. [DOI] [PubMed] [Google Scholar]
  6. Thul J, Hundt F, Will J, Schindler F, Akintürk H, Valeske K, et al. Enoximon vs. milrinon by myocardial dysfunction after cardio‐surgical operations in infants. Zeitschrift fur Kardiologie 1999;88(9):758. [CN‐00340079] [Google Scholar]
  7. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
  8. Schwarzer G. meta: An R package for Meta‐Analysis. R News 2007;7(3):40‐5. [Google Scholar]
  9. Schwarzer G, Rücker G. Statistical methods for detecting and adjusting for publication bias. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen (ZEFQ) 2010;104(4):306‐13. [DOI] [PubMed] [Google Scholar]

Cited by

Sorted by citations

Authors
Burkhardt, B. E., Rücker, G., & Stiller, B.
Affiliations
  • University Children's Hospital Zurich (CH)
  • University of Freiburg (DE)
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2015-03-25
Volume
2015
Issue
3
Pages
CD009515-CD009515
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2135242378
Cited by
81
References
69
Citations by year
2026: 2 · 2025: 4 · 2024: 11 · 2023: 9 · 2022: 7 · 2021: 10 · 2020: 9 · 2019: 7 · 2018: 9 · 2017: 8 · 2016: 4 · 2015: 1
FWCI
0.95
Type
journal article
Language
en
Open access
Locations
  • Cochrane Database of Systematic Reviews (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Congenital Heart Disease Studies
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiovascular Conditions and Treatments
  • Health Sciences › Medicine › Surgery › Hemodynamic Monitoring and Therapy
Keywords
milrinone, low cardiac output syndrome, congenital heart disease, pediatric cardiac surgery, postoperative mortality, levosimendan, dobutamine, inotropic support, postoperative complications, ICU length of stay, mechanical ventilation, infants, neonates, adverse effects, hypotension, cardiac arrhythmias
MeSH terms
Simendan, Cardiac Output, Low, Cardiotonic Agents, Dobutamine, Heart Defects, Congenital, Humans, Hydrazones, Infant, Infant, Newborn, Postoperative Complications, Pyridazines, Syndrome, Time Factors, Randomized Controlled Trials as Topic, Milrinone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review